Detection of antibiotic resistance genes from blood cultures: performance assessment and potential impact on antibiotic therapy management.
Bacteria
/ drug effects
Blood Culture
/ methods
Drug Resistance, Bacterial
Enterobacteriaceae Infections
/ microbiology
Genotype
Genotyping Techniques
/ methods
Humans
Microbial Sensitivity Tests
/ methods
Phenotype
Retrospective Studies
Staphylococcal Infections
/ diagnosis
beta-Lactamases
/ genetics
Antimicrobial stewardship
Antimicrobial susceptibility
Blood culture
Molecular testing
Multi-drug resistance
Journal
The Journal of hospital infection
ISSN: 1532-2939
Titre abrégé: J Hosp Infect
Pays: England
ID NLM: 8007166
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
31
01
2019
accepted:
15
03
2019
pubmed:
25
3
2019
medline:
4
12
2019
entrez:
26
3
2019
Statut:
ppublish
Résumé
Molecular assays may constitute a valid method for timely prediction of antimicrobial resistance and optimization of empirical antibiotic therapies. This study assessed ELITe MGB assays of blood cultures to detect the main carbapenemase and extended-spectrum beta-lactamase (ESBL) genes, Staphylococcus aureus and mec genes in less than 3 h. Excellent agreement was found between the results of genotypic and conventional phenotypic approaches. Retrospective analysis of medical records revealed that approximately 50% of bloodstream infections caused by ESBL-producing Enterobacteriaceae, carbapenemase-producing Enterobacteriaceae or meticillin-resistant S. aureus were initially treated with inactive drugs. Overall, 36.3% of patients could have been treated with appropriate therapy at least 24 h earlier if molecular data had been used.
Identifiants
pubmed: 30905675
pii: S0195-6701(19)30111-2
doi: 10.1016/j.jhin.2019.03.007
pii:
doi:
Substances chimiques
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-469Informations de copyright
Copyright © 2019 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.